John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

We’re working to bring the hope of advanced medicine to more patients.

On Friday nights, Juan Pedro García Hernández goes dancing – but for rest of the time he’s taking care of his mother.

Patients with glaucoma, which affects 60 million people worldwide, can lose up to 40 percent of their sight before they begin to notice any change in vision.

Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.

New Global Head of Ophthalmology Research sees the eye as a frontier of biomedical research.

Jennifer Leeds offers a behind-the-scenes look at the consortia forming to address COVID-19.